Replies to post #39380 on Biotech Values

[Lungman424]

one caveat that should be noted:

Given the small nature of RPRX staff, I thought they would be more incline to sell the company as a whole,once they had some GREAT results behind them. The addition of Chief Medical Officer seems to me a diferent strategy is being contemplated.

I too echo a personal thanks to rfj for introducing me to this company

[bladerunner1717]

rfj, dewophile and other RPRX longs,

Why does the press release not say where the trial was conducted, what sites were involved or who the principal investigators were? That seems strange to me.


Bladerunner

[ghmm]

would be tough to blind an injectable drug with an oral drug

As an aside, Actimmune is a 3x week injectable and it is being blinded. Its a terrible enough disease and then to receive a Placebo injection! One way this could be interpreted is the lack of options speak to what patients/docs will try (though it is available off-label). Also, this is one reason why I speculate that Pirfenidone should complete enrollment much earlier then company forecast (prior posts). One could speculate the hurdle for approval is lower as well.

** Edit **
sorry misread the part about blind injectable with Oral, thought injectable period. You can delete this post
**